论文部分内容阅读
目的观察安体舒通联合坎地沙坦治疗慢性充血性心力衰竭(CHF)的临床疗效。方法将66例缺血性或非缺血性心脏病伴轻中度心力衰竭的患者随机分为2组,治疗组和对照组,33例应用安体舒通和坎地沙坦(治疗组),33例单用坎地沙坦(对照组),在CHF标准用药的基础上,治疗组给予安体舒通25mg/d,坎地沙坦4mg/d,对照组给予坎地沙坦4mg/d,两组治疗类同,疗程6个月。观察治疗前后两组患者的临床症状,超声心动图记录心功能指标。结果治疗后两组的左室的射血分数(LVEF)均有增加,左室收缩末期容积(LVESV)和左室舒张末期容积(LVEDV)均减少,治疗组与对照组比较有差异有统计学意义(P<0.05)。结论安体舒通联合坎地沙坦治疗慢性充血性心力衰竭可以增强疗效,显著改善心功能。
Objective To observe the clinical efficacy of spironolactone combined with candesartan in the treatment of chronic congestive heart failure (CHF). Methods Sixty-six patients with ischemic or non-ischemic heart disease with mild to moderate heart failure were randomly divided into two groups: treatment group and control group, and 33 patients were given spironolactone and candesartan (treatment group) , 33 cases of candesartan alone (control group), on the basis of CHF standard medication, the treatment group given spironolactone 25mg / d, candesartan 4mg / d, the control group was given candesartan 4mg / d, two groups of similar treatment, treatment for 6 months. The clinical symptoms of both groups were observed before and after treatment, and the cardiac function indexes were recorded by echocardiography. Results After treatment, left ventricular ejection fraction (LVEF) increased, left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) decreased in both groups, there were statistically significant differences between the treatment group and the control group Significance (P <0.05). Conclusion Spironolactone combined with candesartan in the treatment of chronic congestive heart failure can enhance the efficacy and significantly improve cardiac function.